The vectored intranasal delivery platform gives us the capability for rapid product development, scale-up, easy and painless immunization during public health emergencies and pandemics
iNCOVACC was developed in partnership with Washington University St. Louis, which had designed and developed the recombinant adenoviral vectored constructs and evaluated them in preclinical studies for efficacy
Covaxin was earlier approved for children 12-18 years of age
MTBVAC is a global public-private project that will be a milestone in the field of vaccinology
The study will be published on the pre-print server, medRXiv, shortly
Six months after receipt of the second Covaxin dose, participants received booster dose of the same. The trial demonstrated long-term safety with no serious events
Covaxin has proven to be safe, well-tolerated, and immunogenic in paediatric subjects in phase II/III study. Neutralizing antibodies in children on an average 1.7 times higher than in adults
Covaxin is the only Covid-19 vaccine to have demonstrated efficacy data from phase III clinical trials against the Delta variant at 65.2%
The facility has the capacity to produce one crore doses per day
Bharat Biotech expects to share further details of the trial results as additional data become available.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)